Trial Profile
A multicenter, real life study evaluating efficacy and safety of Daclatasvir+Sofosbuvir, with or without Ribavirin in Hepatitic C virus genotype 1,2,3,4 patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Daclatasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 25 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017